Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 16/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | HTT | P42858 | 1/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923823 | 0.93 | GPR119 (0.63) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL4013949 | 0.86 | CA12 (0.72) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL382214 | 0.86 | ALDH1A1 (0.65) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL10210061 | 0.85 | ALDH1A1 (0.79) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL17554400 | 0.85 | ALDH1A1 (0.77) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL4115820 | 0.85 | ALDH1A1 (0.77) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL2419811 | 0.84 | GPR119 (0.63) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL377801 | 0.84 | ALDH1A1 (0.75) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL2873727 | 0.84 | ALDH1A1 (0.75) | GPR119ALDH1A1NPC1MAPTMAPK1 | |
| SCHEMBL2338130 | 0.84 | ALDH1A1 (0.77) | GPR119ALDH1A1NPC1MAPTMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX, INC. | 2017-02-09 | — | — | US | disclosed |
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX, INC. | 2017-02-09 | — | — | US | disclosed |
| WO-2015175171-A1 | SUBSTITUTED N-(2-(AMINO)-2-OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX DISCOVERY, INC. (US) | 2015-11-19 | — | — | WO | disclosed |
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1708703-A4 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC (CA) | 2008-04-09 | — | — | EP | disclosed |
| EP-1708703-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-10-11 | — | — | EP | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005059107-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | ENPP2, LPAR2, LPCAT3 | GPR119 1445/4885ALDH1A1 2980/4885NPC1 451/4885 |
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | GPR119 207/4885ALDH1A1 3358/4885NPC1 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.